Mammography-Enhanced Immunotherapy Decision Making in Non-Small Cell Lung Cancer: Charting A New Course
Author(s): Obaje PA; Udam NG; Saludeen HO; Ike WI; Kelechi KV; Udam TG; Armon RA; Jones-Ingwu AU; Edet KJ
Institute(s): 1College of Medical Sciences, UniMaid, Borno; 2,4Community and Clinical Research Division, First On Call Initiative, PortHarcourt; 2Department of Radiology, UCTH; 3Acute medical unit. North Middlesex University Hospital, London; 4Department of Obstetrics and Gynaecology, FMC Asaba; 5Department of Medicine, General Hospital Otu-Jeremi, Delta; 6Department of Medicine and Surgery, Kursk State Medical University, Russia; 7Department of Nursing Science, University of Calabar; 8Department of Haematology UCTH, Calabar; 9Department of Anaesthesiology, University of Calabar Teaching Hospital, Calabar
Volume 8 / Issue 2
Abstract
Non-small cell lung cancer (NSCLC) is one of the most difficult cancers to treat, but advances in immunotherapy have brought new hope to patients. While traditional imaging tools like Computed Tomography (CT) and Positron Emission Tomography (PET) scans are used to guide treatment, there is growing curiosity about whether mammography - a standard breast cancer screening tool - might also have a role to play. In rare cases, mammography has helped detect breast metastases from NSCLC or changes linked to immune-related side effects. Emerging technologies like AI and radiomics also assist researchers in spotting mammography imaging patterns that could hint at how a tumour might respond to immunotherapy.
Number of Pages: 11
Number of Words: 3345
First Page: 1
Last Page: 11